ERBB2 and gastric cancer: This highlights the complementary role of MSI and HER-2 testing in guiding precision oncology approaches [25].In recent years, immunotherapy, particularly in combination with anti-HER-2 therapies in HER-2-positive gastric cancer, has been the focus of increasing research.